SANOFI US SERVICES INC. for SANOFI US SERVICES INC
A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 2nd Quarter - Report (this page) | Jul 17, 2015 | $510,000 | Replaced |
| 2nd Quarter - Amendment | Jul 17, 2015 | $840,000 | Yes |
What was lobbied
8 issue areas, each in the filer's own words, with who lobbied on it and where.
Animals ANI
Education and awareness of issues related to illegal compounding of veterinary drugs for animals
Foreign entity interest: Sanofi US Services Inc. is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commercially benefit Sanofi US Services Inc., so too Sanofi SA, as the parent corporation, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| MARYANNE DOLBEARE DUNLAP | — |
| PATRICK MAYES MCLAIN | — |
Trade (domestic/foreign) TRD
General issues related to Trade Promotion Authority (TPA) including all such provisions of S995 and HR1890 "Bipartisan Congressional Trade Priorities and Accountability Act of 2015" and HR1314 "Ensuring Tax Exempt Organizations the Right to Appeal Act (or Trade Act of 2015)" and such portions of those bills as included in HR 2146 Defending Public Safety Employees Retirement Act and general issues related to the Trans-Pacific Partnership (TPP) and Transatlantic Trade and Investment Partnership (TTIP) negotiations.
Foreign entity interest: Sanofi US Services Inc. is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commercially benefit Sanofi US Services Inc., so too Sanofi SA, as the parent corporation, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ALISON CARA BONEBRAKE | — |
| SEAN CALLINICOS | — |
| MARYANNE DOLBEARE DUNLAP | — |
| PATRICK MAYES MCLAIN | — |
| AMY L REDL | — |
| ANN TAYLOR | — |
Taxation/Internal Revenue Code TAX
Issues related to corporate tax reform, including the deduction of interest, the Orphan drug tax credit, and a strengthened and permanent U.S. R&D tax credit, and all provisions of HR880 "American Research and Competitiveness Act of 2015"; and all provisions of HR1270 and S709 "Restoring Access to Medication Act of 2015"
Foreign entity interest: Sanofi US Services Inc. is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commercially benefit Sanofi US Services Inc., so too Sanofi SA, as the parent corporation, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ALISON CARA BONEBRAKE | — |
| MARYANNE DOLBEARE DUNLAP | — |
| PATRICK MAYES MCLAIN | — |
| AMY L REDL | — |
| ANN TAYLOR | — |
Copyright/Patent/Trademark CPT
International intellectual property issues; general issues related to patent settlements; and all provisions of HR9 "The Innovation Act" and S1137 "Protecting American Talent and Entrepreneurship Act of 2015"
Foreign entity interest: Sanofi US Services Inc. is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commercially benefit Sanofi US Services Inc., so too Sanofi SA, as the parent corporation, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ALISON CARA BONEBRAKE | — |
| SEAN CALLINICOS | — |
| MARYANNE DOLBEARE DUNLAP | — |
| PATRICK MAYES MCLAIN | — |
| AMY L REDL | — |
| ANN TAYLOR | — |
Economics/Economic Development ECN
General issues related to the importance of foreign direct investment in the U.S.
Foreign entity interest: Sanofi SA, the foreign parent corporation of Sanofi US Services Inc. invests in its business in the U.S.
| Lobbyist | Covered position, as disclosed |
|---|---|
| PATRICK MAYES MCLAIN | — |
| ANN TAYLOR | — |
Health Issues HCR
Education and awareness of the 2014-2015 influenza season; education and awareness of Avian influenza; education and awareness of pandemic and biodefense funding; education and awareness of Dengue; general issues related to FDA and NIH funding; all provisions of S320 and HR744 "Medical Innovation Act"; the importance of immunizations for herd immunity; all issues related to the 21st Century Cures Initiative including all provisions of HR6 "To accelerate the discovery, development, and delivery of 21st century cures, and for other purposes (21st Century Cures Act)"; general issues related to the importation of pharmaceutical products, including all provisions of S122 "Safe and Affordable Drugs from Canada Act of 2015; all provisions of Preserving Access to Orphan Drugs Act (discussion draft); The President's Budget Proposal - the proposal related to reducing from 12 years to 7 years the data exclusivity period for innovator biologics and the proposal related to generating additional savings from the Independent Payment Advisory Board (IPAB); education and awareness of diabetes and related treatments; issues related to the need for research into clinical tools to diagnose and assess the severity of atopic dermatitis; and education and awareness of cardiovascular disease and related treatments.
Foreign entity interest: Sanofi US Services Inc. is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commercially benefit Sanofi US Services Inc., so too Sanofi SA, as the parent corporation, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ALISON CARA BONEBRAKE | — |
| SEAN CALLINICOS | — |
| MARYANNE DOLBEARE DUNLAP | — |
| PATRICK MAYES MCLAIN | — |
| AMY L REDL | — |
| ANN TAYLOR | — |
Medicare/Medicaid MMM
Issues related to the Medicaid rebate policy; general issues related to the Mediare Part D Program; coverage and reimbursement for the Medicare Part D prescription drug benefit and all provisions of S31 "Medicare Prescription Drug Price Negotiation Act"; proposals set forth in the President's Budget Request related to restructuring copayments for generic and brand drugs for low income beneficiaries; reducing reimbursement for Medicare Part B medicines; all provisions of HR2 "Medicare Access and CHIP Reauthorization Act of 2015"; all provisions of HR2005 and S1083 "Medicare Drug Savings Act of 2015" and general issues related to chronic care reform in the Medicare program.
Foreign entity interest: Sanofi US Services Inc. is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commercially benefit Sanofi US Services Inc., so too Sanofi SA, as the parent corporation, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ALISON CARA BONEBRAKE | — |
| SEAN CALLINICOS | — |
| MARYANNE DOLBEARE DUNLAP | — |
| PATRICK MAYES MCLAIN | — |
| AMY L REDL | — |
| ANN TAYLOR | — |
Pharmacy PHA
General issues related to the 340B Federal Drug Pricing Program
Foreign entity interest: Sanofi US Services Inc. is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commercially benefit Sanofi US Services Inc., so too Sanofi SA, as the parent corporation, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ALISON CARA BONEBRAKE | — |
| SEAN CALLINICOS | — |
| PATRICK MAYES MCLAIN | — |
| AMY L REDL | — |
Affiliated organisations
| Organisation | Location |
|---|---|
| CHATTEM, INC. | Chattanooga, TN, US |
| SANOFI PASTEUR | Swiftwater, PA, US |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.